Three FDA offices open doors in China
This article was originally published in The Silver Sheet
Executive Summary
FDA opened three new offices in China the week of Nov. 17 in a move approved by the U.S. State Department in March. The eight FDA senior staffers selected to work in the Beijing, Guangzhou and Shanghai offices are inspectors and senior technical experts in foods, medicines and medical devices, the U.S. Department of Health and Human Services notes. "By having a presence in other parts of the world, we can work more closely with manufacturers and other governments, better share best practices and further ensure ... quality and safety," says HHS Secretary Mike Leavitt, who, along with FDA Commissioner Andrew von Eschenbach, traveled to the three cities late last month to meet with manufacturers and Chinese government officials to discuss policy and governance reforms aimed at improving the safety of medical products and food. HHS also is working to have an FDA presence in India, Europe, Latin America and the Middle East
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.